Für diese Kanzlei können nur begrenzte Informationen angezeigt werden. Für die folgenden Kanzleien werden vollständigere Informationen angezeigt:
Chicago-based boutique firm Rakoczy Molino Mazzochi Siwik LLP is highly regarded for its strong litigation capabilities in the biopharma sector. The team represents a broad array of pharma and biopharma generic drugs in high-stakes patent litigation against brand-name drug owners in Hatch-Waxman cases. The practice is co-chaired by managing partners Paul Molino and William Rakoczy. Molino boasts a strong track record at the Court of Appeals for biosimilars and biologics, while Rakoczy is recognized as ‘one of the best trial attorneys’ in Hatch-Waxman and BPCIA litigation. Other key practitioners specializing in Hatch-Waxman proceedings include Deanne Mazzochi, Kevin Warner and Rachel Pernic Waldron. Lara FitzSimmons combines her expertise in Hatch-Waxman proceedings with her background in life sciences transactions. Eric Hunt has further strengthened the team with his expertise in biosimilars, particularly for start-up companies.
Legal 500 redaktioneller Kommentar
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘RMMS team is very strong in litigation trial for biopharmaceuticals. They have an excellent team with a vast experience. They strive to achieve success for their clients.’
‘William Rakoczy is the attorney with whom I have worked in multiple patent litigations. He is very smart with excellent oratory skills for Litigation trials. He has delivered success for our company in our earlier patent litigation.’
Kernmandanten
- KD Pharma Group
- Sandoz
Highlight-Mandate
- Secured non-infringement win on behalf of client, Aveva Drug Delivery Systems, Inc., in connection with litigation involving Scilex Pharmaceuticals Inc.’s, ITOCHU CHEMICAL FRONTIER Corporation’s, and Oishi Koseido Co., Ltd.’s post-herpetic neuralgia drug,ZTLido® (lidocaine topical system) 1.8%.
- Defeated Galderma Laboratories’ request for a temporary restraining order and preliminary injunction, which sought to prevent Lupin from manufacturing, marketing, selling, or using its generic drug during Galderma’s appeal of the district court’s decision involving the rosacea drug, Oracea®(doxycycline) capsules.